Juan Santacruz
Research Subjects
Juan Santacruz has a total of 124 co-authors. Here are the top co-authors by number of shared publications:
- Ángel Cristóbal Santacruz Tipanta
Pafram Hemodiafiltration Unit, Complementary Health Network, Sucúa, Ecuador
3 shared publications - Franklin Mora-Bravo
Hemodiafiltration Unit, Pafram Hemodiafiltration Unit, Sucúa, ECU
2 shared publications - Willan Patricio Robles Abarca
Hospital General Ambato IESS, Ecuador
2 shared publications Adeera Levin
Division of Nephrology, Department of Medicine, University of British Columbia, Vancouver, British Columbia, Canada
1 shared publication- Adela Anguisaca
Servicio de Nefrología, Hospital General Docente de Calderón, Ministerio de Salud Pública, Quito, Ecuador
1 shared publication - Ailiyomar Perez
Menydial
1 shared publication
Latest Publications
- 25 November 2025
- Published by S. Karger AG in Nephron
- p. 1-12
Outcomes and Decision Stability in Older Adults following Structured Counseling on Dialysis versus Conservative Management for Kidney Failure: A Prospective Study
Background: The management of kidney failure in older adults has increasingly adopted patient-centered approaches, with conservative kidney management (CKM) recognized as a valid alternative to dialysis in selected cases. Structured counseling is commonly used to support informed decision-making and align treatment with patient goals. However, evidence on its structured application and impact on treatment decisions in this population remains limited. This study evaluates the clinical characteristics, treatment choices, decision stability, and outcomes of older adults with kidney failure who, after a structured counseling session (“Welcome Meeting”) at La Paz University Hospital, chose either CKM or dialysis. Methods: This prospective, observational, single-center cohort study (April 2015 to December 2019) included participants aged >75 years with CKD-EPI <12 mL/min (5, and functional impairment (Barthel Index <95 or Palliative Performance Scale <60). All participants received a structured counseling session to support treatment decision-making. Participants then chose either dialysis or CKM. Predictors included treatment choice, clinical outcomes, symptom burden, and healthcare utilization. Decision stability was defined as sustained adherence to the initial treatment choice over the course of follow-up. Analyses were adjusted for potential confounders including age, sex, comorbidity, and functional status. Data were analyzed using SPSS version 27. Results: A total of 103 participants were included (mean age: 84.9 ± 5.5 years); 72% chose CKM and 28% opted for dialysis. CKM participants were older, more often female (p = 0.009), and had greater functional and cognitive impairment (p < 0.001). They also reported more weakness or lack of energy (p = 0.03), constipation (p = 0.03), and poor mobility (p < 0.001) at baseline. At the standardized follow-up assessment, depressive symptoms measured with the IPOS-Renal scale showed a significant reduction in the dialysis group (p = 0.043), while vomiting (p = 0.021) and sore or dry mouth (p = 0.049) increased significantly in the CKM group. Healthcare utilization was higher among dialysis participants. Of the 69 deaths, 65 occurred in the CKM group. Decision stability revealed only 5% of CKM participants switching later to dialysis, with no treatment transitions observed in the dialysis group. Conclusion: After a structured counseling session, elderly kidney failure participants who chose CKM were older, female, and presented greater cognitive and functional impairment. This approach supported informed choices and was associated with a high adherence to the initial treatment decision. Further studies are needed to expand this line of research.
- 25 November 2025
- Published by S. Karger AG in Nephron
- p. 1-12
Outcomes and Decision Stability in Older Adults following Structured Counseling on Dialysis versus Conservative Management for Kidney Failure: A Prospective Study
Background: The management of kidney failure in older adults has increasingly adopted patient-centered approaches, with conservative kidney management (CKM) recognized as a valid alternative to dialysis in selected cases. Structured counseling is commonly used to support informed decision-making and align treatment with patient goals. However, evidence on its structured application and impact on treatment decisions in this population remains limited. This study evaluates the clinical characteristics, treatment choices, decision stability, and outcomes of older adults with kidney failure who, after a structured counseling session (“Welcome Meeting”) at La Paz University Hospital, chose either CKM or dialysis. Methods: This prospective, observational, single-center cohort study (April 2015 to December 2019) included participants aged >75 years with CKD-EPI <12 mL/min (5, and functional impairment (Barthel Index <95 or Palliative Performance Scale <60). All participants received a structured counseling session to support treatment decision-making. Participants then chose either dialysis or CKM. Predictors included treatment choice, clinical outcomes, symptom burden, and healthcare utilization. Decision stability was defined as sustained adherence to the initial treatment choice over the course of follow-up. Analyses were adjusted for potential confounders including age, sex, comorbidity, and functional status. Data were analyzed using SPSS version 27. Results: A total of 103 participants were included (mean age: 84.9 ± 5.5 years); 72% chose CKM and 28% opted for dialysis. CKM participants were older, more often female (p = 0.009), and had greater functional and cognitive impairment (p < 0.001). They also reported more weakness or lack of energy (p = 0.03), constipation (p = 0.03), and poor mobility (p < 0.001) at baseline. At the standardized follow-up assessment, depressive symptoms measured with the IPOS-Renal scale showed a significant reduction in the dialysis group (p = 0.043), while vomiting (p = 0.021) and sore or dry mouth (p = 0.049) increased significantly in the CKM group. Healthcare utilization was higher among dialysis participants. Of the 69 deaths, 65 occurred in the CKM group. Decision stability revealed only 5% of CKM participants switching later to dialysis, with no treatment transitions observed in the dialysis group. Conclusion: After a structured counseling session, elderly kidney failure participants who chose CKM were older, female, and presented greater cognitive and functional impairment. This approach supported informed choices and was associated with a high adherence to the initial treatment decision. Further studies are needed to expand this line of research.
- Open Access
- 5 September 2025
- Published by Sociedad Ecuatoriana de Nefrologia, Dialisis y Trasplantes in Revista de la Sociedad Ecuatoriana de Nefrología, Diálisis y Trasplante
- Vol. 14 (1) , 30-38
Ecografía portátil de mano como alternativa accesible en países con recursos limitados
Background: Percutaneous native kidney biopsy (PNKB) is crucial for diagnosing renal pathology. In resource-limited environments, handheld ultrasound devices may offer a cost-effective alternative for procedural guidance. We aimed to compare the safety and diagnostic yield of PNKB performed with handheld versus high-end ultrasound systems. Methods: retrospective cohort study at Calderón General Teaching Hospital (2021–2023), including adult patients undergoing ultrasound-guided PNKB. Procedures were categorized by device: handheld (Butterfly iQ with iPhone) versus high-end (Philips Sparq). We collected data on demographics, biopsy indications, number of passes, glomerular yield, histological diagnosis, and complications. Diagnostic adequacy and safety outcomes were compared using chi-square and t-tests. Results: A total of 57 PNKBs were analyzed (22 handheld; 35 high-end). Patients were 56% female, with a mean age of 33.8 ± 12.7 years. The average number of glomeruli obtained per core was 15.7 ± 8.1. Overall, 82.5% of procedures were free of complications; 17.5% had minor complications (pain ≥12 h, hematoma, or macroscopic hematuria), and no major complications occurred. Complication-free rates were similar between groups (handheld: 72.7% vs. high-end: 88.6%; p = 0.39). Diagnostic adequacy was achieved in 85.7% of biopsies, with no significant difference between handheld (81.8%) and high-end (88.2%; p = 0.50). Conclusion: Handheld ultrasound-guided PNKB demonstrates comparable safety and diagnostic yield to high-end systems, offering a low-cost and effective alternative in resource-limited settings. Wider adoption may enhance access to renal biopsy without compromising quality or safety.
- 5 September 2025
- Published by Sociedad Ecuatoriana de Nefrologia, Dialisis y Trasplantes in Revista de la Sociedad Ecuatoriana de Nefrología, Diálisis y Trasplante
- Vol. 14 (1) , 30-38
Open AccessEcografía portátil de mano como alternativa accesible en países con recursos limitados
Background: Percutaneous native kidney biopsy (PNKB) is crucial for diagnosing renal pathology. In resource-limited environments, handheld ultrasound devices may offer a cost-effective alternative for procedural guidance. We aimed to compare the safety and diagnostic yield of PNKB performed with handheld versus high-end ultrasound systems. Methods: retrospective cohort study at Calderón General Teaching Hospital (2021–2023), including adult patients undergoing ultrasound-guided PNKB. Procedures were categorized by device: handheld (Butterfly iQ with iPhone) versus high-end (Philips Sparq). We collected data on demographics, biopsy indications, number of passes, glomerular yield, histological diagnosis, and complications. Diagnostic adequacy and safety outcomes were compared using chi-square and t-tests. Results: A total of 57 PNKBs were analyzed (22 handheld; 35 high-end). Patients were 56% female, with a mean age of 33.8 ± 12.7 years. The average number of glomeruli obtained per core was 15.7 ± 8.1. Overall, 82.5% of procedures were free of complications; 17.5% had minor complications (pain ≥12 h, hematoma, or macroscopic hematuria), and no major complications occurred. Complication-free rates were similar between groups (handheld: 72.7% vs. high-end: 88.6%; p = 0.39). Diagnostic adequacy was achieved in 85.7% of biopsies, with no significant difference between handheld (81.8%) and high-end (88.2%; p = 0.50). Conclusion: Handheld ultrasound-guided PNKB demonstrates comparable safety and diagnostic yield to high-end systems, offering a low-cost and effective alternative in resource-limited settings. Wider adoption may enhance access to renal biopsy without compromising quality or safety.
- Open Access
- 3 March 2025
- Published by Sociedad Ecuatoriana de Nefrologia, Dialisis y Trasplantes in Revista de la Sociedad Ecuatoriana de Nefrología, Diálisis y Trasplante
- Vol. 13 (2) , 91-97
Prevalence of multiple myeloma in patients on hemodialysis programs
Introduction: Multiple myeloma (MM) is a hematological malignancy that often causes kidney failure, affecting more than 50% of MM patients. Kidney damage in MM is primarily due to cast nephropathy, light chain deposition disease, and amyloidosis. However, there are no data on MM patients undergoing hemodialysis in Ecuador. This study aims to report the prevalence of MM in the country's hemodialysis units. Methods: This observational, descriptive, cross-sectional, multicenter study evaluated the prevalence of MM in hemodialysis patients in Ecuador. A survey was distributed to 23 nephrologists, collecting data on the total number of hemodialysis patients and those diagnosed with MM. Prevalence was calculated using the formula: Prevalence = (MM patients / Total hemodialysis patients) × 1000. Data were analyzed using nonparametric methods in R v4.3.2, with 99% confidence intervals. Results: were diagnosed with MM, yielding a prevalence of 1.1% (95% CI: 0.7% to 1.6%), or 11.3 cases per 1000 hemodialysis patients. The number of MM cases varied by city, with the highest number reported in Portoviejo (10 cases) and none in Riobamba. Conclusion: The prevalence of MM in Ecuador is consistent with international reports, with similar findings in the United States (1.0%), Nigeria (0.81%), and other Latin American countries. These findings highlight the need for a national registry to better understand the needs of MM patients on hemodialysis.
- 3 March 2025
- Published by Sociedad Ecuatoriana de Nefrologia, Dialisis y Trasplantes in Revista de la Sociedad Ecuatoriana de Nefrología, Diálisis y Trasplante
- Vol. 13 (2) , 91-97
Open AccessPrevalence of multiple myeloma in patients on hemodialysis programs
Introduction: Multiple myeloma (MM) is a hematological malignancy that often causes kidney failure, affecting more than 50% of MM patients. Kidney damage in MM is primarily due to cast nephropathy, light chain deposition disease, and amyloidosis. However, there are no data on MM patients undergoing hemodialysis in Ecuador. This study aims to report the prevalence of MM in the country's hemodialysis units. Methods: This observational, descriptive, cross-sectional, multicenter study evaluated the prevalence of MM in hemodialysis patients in Ecuador. A survey was distributed to 23 nephrologists, collecting data on the total number of hemodialysis patients and those diagnosed with MM. Prevalence was calculated using the formula: Prevalence = (MM patients / Total hemodialysis patients) × 1000. Data were analyzed using nonparametric methods in R v4.3.2, with 99% confidence intervals. Results: were diagnosed with MM, yielding a prevalence of 1.1% (95% CI: 0.7% to 1.6%), or 11.3 cases per 1000 hemodialysis patients. The number of MM cases varied by city, with the highest number reported in Portoviejo (10 cases) and none in Riobamba. Conclusion: The prevalence of MM in Ecuador is consistent with international reports, with similar findings in the United States (1.0%), Nigeria (0.81%), and other Latin American countries. These findings highlight the need for a national registry to better understand the needs of MM patients on hemodialysis.
- Open Access
- 17 January 2025
- Published by Springer Nature in BMC Nephrology
- Vol. 26 (1) , 1-11
Blood pressure control with active ultrafiltration measures and without antihypertensives is essential for survival in hemodiafiltration and hemodialysis programs for patients with CKD: a prospective observational study
Background: High blood pressure is a prevalent condition in patients with chronic kidney disease on hemodialysis. Adequate control of high blood pressure is essential to reducing deaths in this group. The present study aimed to observe mortality prospectively in a group of patients in hemodialysis and hemodiafiltration programs in whom the use of antihypertensives was optimized with the point-of-care dry weight (POC-DW) technique. Methods: The present observational, prospective study was carried out at the Pafram hemodiafiltration unit in Morona Santiago, Ecuador, and the hemodialysis unit of the Fundación Renal del Ecuador in Guayaquil, Ecuador, from August 2019 to December 2023. Patients who were receiving hemodiafiltration were included. Weight was optimized with POC-DW for eight weeks. In Group 1, patients whose use of antihypertensive drugs was not required to control systolic blood pressure with a value less than 150 mmHg predialysis, less than 130 mmHg postdialysis, and a peridialytic blood pressure (defined as post-HD minus pre-HD SBP) between 0 and − 20 mmHg were analyzed. In Group 2, patients who required antihypertensive drugs for not meeting the aims of systolic blood pressure were included. The variables included clinical, demographic, mortality, description of the treatment, and routine laboratory tests in dialysis programs. The sample was nonprobabilistic. Survival analysis was performed for the study groups. The log-rank test (Mantel-Cox) was used for survival comparisons. Results: The study included 106 patients. Optimal blood pressure control without antihypertensive treatment was achieved in 52 patients (49.1%) (Group 1). In 54 patients (50.9%), antihypertensive agents were required (Group 2). There was more significant mortality in the group that received antihypertensives: 11 patients in group 1 (21.2%) versus 25 patients in group 2 (46.3%) (P = 0.005). Survival was more significant in group 1, with an HR of 2.2163 (1.125–4.158) (P = 0.0243). Conclusion: In hemodiafiltration and hemodialysis programs, blood pressure control with active ultrafiltration measures and without using antihypertensives is essential for survival in patients with CKD.
- 17 January 2025
- Published by Springer Nature in BMC Nephrology
- Vol. 26 (1) , 1-11
Open AccessBlood pressure control with active ultrafiltration measures and without antihypertensives is essential for survival in hemodiafiltration and hemodialysis programs for patients with CKD: a prospective observational study
Background: High blood pressure is a prevalent condition in patients with chronic kidney disease on hemodialysis. Adequate control of high blood pressure is essential to reducing deaths in this group. The present study aimed to observe mortality prospectively in a group of patients in hemodialysis and hemodiafiltration programs in whom the use of antihypertensives was optimized with the point-of-care dry weight (POC-DW) technique. Methods: The present observational, prospective study was carried out at the Pafram hemodiafiltration unit in Morona Santiago, Ecuador, and the hemodialysis unit of the Fundación Renal del Ecuador in Guayaquil, Ecuador, from August 2019 to December 2023. Patients who were receiving hemodiafiltration were included. Weight was optimized with POC-DW for eight weeks. In Group 1, patients whose use of antihypertensive drugs was not required to control systolic blood pressure with a value less than 150 mmHg predialysis, less than 130 mmHg postdialysis, and a peridialytic blood pressure (defined as post-HD minus pre-HD SBP) between 0 and − 20 mmHg were analyzed. In Group 2, patients who required antihypertensive drugs for not meeting the aims of systolic blood pressure were included. The variables included clinical, demographic, mortality, description of the treatment, and routine laboratory tests in dialysis programs. The sample was nonprobabilistic. Survival analysis was performed for the study groups. The log-rank test (Mantel-Cox) was used for survival comparisons. Results: The study included 106 patients. Optimal blood pressure control without antihypertensive treatment was achieved in 52 patients (49.1%) (Group 1). In 54 patients (50.9%), antihypertensive agents were required (Group 2). There was more significant mortality in the group that received antihypertensives: 11 patients in group 1 (21.2%) versus 25 patients in group 2 (46.3%) (P = 0.005). Survival was more significant in group 1, with an HR of 2.2163 (1.125–4.158) (P = 0.0243). Conclusion: In hemodiafiltration and hemodialysis programs, blood pressure control with active ultrafiltration measures and without using antihypertensives is essential for survival in patients with CKD.
- Open Access
- 3 February 2024
- Published by Sociedad Ecuatoriana de Nefrologia, Dialisis y Trasplantes in Revista de la Sociedad Ecuatoriana de Nefrología, Diálisis y Trasplante
- Vol. 12 (1) , 9-12
Falsa positivización del antígeno de superficie del virus de la Hepatitis B (HBsAg) tras vacunación.
Introduction: The chronic hemodialysis population has a greater exposure and risk to the hepatitis B virus, which is why immunoprophylaxis using the double dose scheme (40mcg) on days 0-30-60-180, with application of this regimen for a second extra time in nonresponders, is common practice in this population. Clinical case: This is a 67-year-old male patient of Afro-Ecuatorian ethnicity who started hemodialysis (HD) in August 2023 for chronic kidney disease (CKD) secondary to diabetic nephropathy. When starting HD, he had negative serology for hepatitis and negativity for HBsAg. For this reason, he received his first vaccination dose on November 29, 2023, and on December 15, he had HBsAg positivity with values of 4.14 S/CO (≥1 positive), with Ac-ANTI-HBSAG levels < 2 IU/L. Management: Given the findings, it was decided to isolate the patient with control of liver function, which is normal, and a new test of HBsAg levels in 15 days, which were subsequently negative. Conclusion: In this case, we want to remember the false politicization of HBsAg after vaccination in hemodialysis patients, a situation associated with the vaccine being composed of live attenuated viruses or recombinant particles of surface proteins.
- 3 February 2024
- Published by Sociedad Ecuatoriana de Nefrologia, Dialisis y Trasplantes in Revista de la Sociedad Ecuatoriana de Nefrología, Diálisis y Trasplante
- Vol. 12 (1) , 9-12
Open AccessFalsa positivización del antígeno de superficie del virus de la Hepatitis B (HBsAg) tras vacunación.
Introduction: The chronic hemodialysis population has a greater exposure and risk to the hepatitis B virus, which is why immunoprophylaxis using the double dose scheme (40mcg) on days 0-30-60-180, with application of this regimen for a second extra time in nonresponders, is common practice in this population. Clinical case: This is a 67-year-old male patient of Afro-Ecuatorian ethnicity who started hemodialysis (HD) in August 2023 for chronic kidney disease (CKD) secondary to diabetic nephropathy. When starting HD, he had negative serology for hepatitis and negativity for HBsAg. For this reason, he received his first vaccination dose on November 29, 2023, and on December 15, he had HBsAg positivity with values of 4.14 S/CO (≥1 positive), with Ac-ANTI-HBSAG levels < 2 IU/L. Management: Given the findings, it was decided to isolate the patient with control of liver function, which is normal, and a new test of HBsAg levels in 15 days, which were subsequently negative. Conclusion: In this case, we want to remember the false politicization of HBsAg after vaccination in hemodialysis patients, a situation associated with the vaccine being composed of live attenuated viruses or recombinant particles of surface proteins.
- 29 December 2022
- Published by Wolters Kluwer Health in Kidney360
- Vol. 3 (12) , 2131-2135
Global Dialysis Perspectives: Ecuador
This is an Early Access article. Please select the PDF button, above, to view it.
- 29 December 2022
- Published by Wolters Kluwer Health in Kidney360
- Vol. 3 (12) , 2131-2135
Global Dialysis Perspectives: Ecuador
This is an Early Access article. Please select the PDF button, above, to view it.